PFE Overview
Upcoming Projects (PFE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (PFE)
-
Discussing private and commercial payer reimbursement strategies in the US for Pfizer's Paxlovid with a billing expert who interacts with pharmaceutical companies related to COVID-19 treatment.
Ticker: PFE
Executed On: Apr 21, 2023 at 04:00 PM EDT -
Examining the potential of Valneva and Pfizer's Lyme disease vaccine, VLA15
Tickers: VALN, PFE
Executed On: Nov 01, 2022 at 01:00 PM EDT -
Digging into S1P1 modulators as treatment for Ulcerative Colitis with a focus on Zeposia (Ozanimod), Etrasimod, CBP-307 & VTX002
Tickers: BMY, PFE, CNTB, VTYX
Executed On: Sep 23, 2022 at 02:00 PM EDT -
Examining the use of Nurtech in migraines and where AXS-07 could fit in if approved
Tickers: AXSM, BHVN, PFE
Executed On: Jul 22, 2022 at 11:00 AM EDT -
A look into the proposed mRNA-based vaccine for the prevention of Shingles
Tickers: BNTX, PFE
Executed On: May 24, 2022 at 02:00 PM EDT -
A look into the current and developing S1P1 modulators as treatment for Ulcerative Colitis
Tickers: PFE, BMY, CNTB, VTYX
Executed On: Apr 22, 2022 at 01:00 PM EDT -
A Second Look: Discussing the potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 24, 2022 at 12:00 PM EST -
A look at potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 18, 2022 at 01:00 PM EST
Expired Projects (PFE)
-
Discussing Pfizer’s respiratory syncytial virus vaccine, Abrysvo
Ticker: PFE
Execute By: May 31, 2023 -
Examining the Market Potential for JAKs treating moderate-to-severe alopecia areata
Tickers: CNCE, LLY, PFE, INCY
Execute By: Jun 23, 2022 -
Exploring the recent hemophilia A - SB-525 gene therapy data from Sangamo
Tickers: SGMO, PFE
Execute By: Aug 30, 2019 -
Discussing the Effectiveness and Market Potential of Pfizer's (PFE) Crisaborole in Atopic Dermatitis After January 7th PDUFA Date
Ticker: PFE
Execute By: Feb 01, 2017 -
Electroporation Expert Interview: An Overview and its Pharmaceutical Potential
Tickers: INO, PFE, RHHBY, ROLL
Execute By: Nov 02, 2016
Included with Membership
Upcoming & Overdue Catalysts (PFE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (PFE)
-
Pfizer/BioNTech's BNT162b2 vaccine against SARS-CoV-2 U.S. EUA application expected this month
Tickers: PFE, BNTX
Occurred on: Nov 20, 2020 -
U.S. FDA Approves Pfizer’s (PFE) Biosimilar NIVESTYM (filgrastim-aafi)
Ticker: PFE
Occurred on: Jul 18, 2018 -
Advisory Committee Meeting for Pfizer's(PFE) Staphylococcus aureus vaccine for pre-surgical prophylaxis expected November 7 2017
Ticker: PFE
Occurred on: Nov 07, 2017 -
Viiv Healthcare Presents Results from 2 Phase 3 Studies Evaluating Dolutegravir + Rilpivirine in HIV Maintenance
Tickers: VIIV HEALTHCARE, PFE, JNJ, GSK, SGIOF
Occurred on: Dec 20, 2016 -
PDUFA Date of January 7, 2017 for Pfizer's (PFE) Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis
Ticker: PFE
Occurred on: Dec 14, 2016 -
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Ticker: PFE
Occurred on: Nov 29, 2016 -
Pfizer (PFE) Terminates Development of Cholesterol Lowering Candidate Bococizumab
Ticker: PFE
Occurred on: Nov 01, 2016 -
3rd and Final Presidential Debate between Donald Trump and Hillary Clinton at the University of Nevada, Las Vegas, 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, MYL, GILD
Occurred on: Oct 20, 2016 -
Esperion Therapeutics (ESPR) Announces Phase 2 Data Evaluating Bempedoic Acid Added to Atorvastatin in Hypercholesterolemia
Tickers: ESPR, PFE
Occurred on: Oct 13, 2016 -
Pfizer (PFE) Presents Phase 3 S-TRAC Results Evaluating Sutent (sunitinib) in Patients with Renal Cell Carcinoma
Ticker: PFE
Occurred on: Oct 10, 2016 -
First Presidential debate between Donald Trump and Hillary Clinton at Hofstra University, New York, from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, GILD, MYL
Occurred on: Sep 26, 2016 -
Pfizer's (PFE) IBRANCE + Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer Recommended for Approval by European Ad Comm
Ticker: PFE
Occurred on: Sep 16, 2016 -
Pfizer (PFE) Announces Phase 3 REFLECTIONS B537-02 Data Evaluating Remicade Biosimilar in Rheumatoid Arthritis
Tickers: PFE, NVS
Occurred on: Sep 16, 2016 -
Merck (MRK) and Pfizer (PFE) Announce Phase 3 Results for Type 2 Diabetes Candidate Ertugliflozin
Tickers: MRK, PFE
Occurred on: Sep 15, 2016 -
Pfizer Receives FDA Approval for Prevnar 13 in Adults Age 18 Through 49
Ticker: PFE
Occurred on: Jul 12, 2016 -
BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer
Tickers: BIND, PFE
Occurred on: Jul 01, 2016 -
Phase 3 Studies of Tanezumab for Chronic Pain Resume After Partial Clinical Hold
Tickers: PFE, LLY
Occurred on: Mar 23, 2016 -
FDA’s Arthritis Advisory Committee Recommends Approval of Celltrion’s CT-P13, a Proposed Biosimilar Infliximab, for All Eligible Indications
Tickers: CELLTRION, PFE, MRK, JNJ
Occurred on: Feb 10, 2016 -
FDA reviewers support Celltrion's biosimilar Remicade, ahead of the Ad Comm meeting on February 9
Tickers: CELLTRION, PFE, JNJ, MRK
Occurred on: Feb 05, 2016 -
Revance's (RVNC) RT002 Superior to Allergan's (AGN) BOTOX in Phase 2 Study Evaluating Treatment of Frown Lines
Tickers: RVNC, PFE, VRX, AGN
Occurred on: Oct 29, 2015 -
Allergan (AGN) Launches Over-the-counter Artificial Tear REFRESH OPTIVE Gel Drops for Dry Eye Symptoms
Tickers: AGN, PFE
Occurred on: Oct 21, 2015 -
Allergan (AGN) Issues Statement Regarding Specialty Pharmacy Utilization and Resumes Trading
Tickers: AGN, PFE, VRX
Occurred on: Oct 21, 2015 -
Allergan (AGN) Completes Acquisition of AqueSys and XEN45 for $300 Million
Tickers: AGN, PFE
Occurred on: Oct 19, 2015 -
FDA Grants Pfizer's (PFE) Inotuzumab Ozogamicin Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia
Ticker: PFE
Occurred on: Oct 19, 2015 -
Allergan (AGN) Presents Data From Harmony Study on Combined Facial Aesthetic Treatment With Botox, Dermal Fillers, and Bimatoprost
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015 -
Allergan (AGN) Presents Paper Titled "Facial Treatment Preferences in Aesthetically-Oriented Men" at American Society of Dermatologic Surgery Meeting
Tickers: AGN, PFE, VRX
Occurred on: Oct 17, 2015 -
Boehringer Ingelheim's Praxbind Approved by FDA for Use As an Emergency Reversing Agent in Patients Taking Pradaxa
Tickers: BOEHRINGER INGELHEIM, PTLA, BXLT, PFE, BMY
Occurred on: Oct 16, 2015
Strategic Initiatives (PFE)
-
Myovant Sciences (MYOV) and Pfizer (PFE) Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Tickers: MYOV, PFE
Announcement Date: Dec 28, 2020 -
Pfizer (PFE) spin off Upjohn Business merges with Mylan N.V. (MYL), forming Viatris Inc. (VTRS)
Tickers: PFE, MYL
Announcement Date: Nov 16, 2020 -
Pfizer (PFE) is set to purchase 5,000,000 of Homology’s (FIXX) common stock at a price of $12.00 per share
Tickers: FIXX, PFE
Announcement Date: Nov 09, 2020 -
Antares Pharma (ATRS) Enters into a Development Agreement with Pfizer (PFE) to develop a combination drug device rescue pen
Tickers: ATRS, PFE
Announcement Date: Aug 06, 2018 -
ICU Medical (ICUI) Announces $1B Cash & Stock Purchase of Pfizer's (PFE) Hospira Infusion Therapy Unit
Tickers: ICUI, PFE
Announcement Date: Oct 06, 2016 -
Pfizer (PFE) Decides Not to Split Company, Will Operate as One Company With Two Distinct and Complementary Businesses to Maximize Future Value Creation
Ticker: PFE
Announcement Date: Sep 26, 2016 -
Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca
Tickers: PFE, AZN
Announcement Date: Aug 24, 2016 -
Pfizer near $14 billion acquisition of Medivation
Tickers: PFE, MDVN
Announcement Date: Aug 21, 2016 -
BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets
Tickers: BIND, PFE
Announcement Date: Jul 26, 2016 -
Pfizer Completes Acquisition of Anacor
Tickers: PFE, ANAC
Announcement Date: Jun 23, 2016 -
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
Tickers: MRK, PFE, VSTM
Announcement Date: Mar 03, 2016 -
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Tickers: BMY, PFE, PTLA
Announcement Date: Feb 02, 2016